-
05:58:08 AM
Sign in with email
Forgot your password?
Register with email
Account Verification

NVCR Stock News

06/21/22 8:00 AM
Nasdaq : NVCR
Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer
Novocure today announced the first patient has been enrolled in its phase 2 pilot KEYNOTE-B36 study, conducted in collaboration with MSD, a tradename of Merck& Co., Inc., Rahway, NJ, USA. KEYNOTE-B36 is designed to evaluate the safety and effectiveness of Tumor Treating Fields together with KEYTRUDA ®, MSD’ s anti-PD-1 therapy, for the first-line treatment of...
RHEA-AI
neutral
05/26/22 8:00 AM
Nasdaq : NVCR
Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Newly Diagnosed Glioblastoma
Novocure today announced it has entered into a clinical trial collaboration agreement with MSD, a tradename of Merck& Co., Inc., Rahway, NJ, USA, to study the use of Tumor Treating Fields concomitant with MSD’ s anti-PD-1 therapy KEYTRUDA ® for the treatment of patients with newly diagnosed glioblastoma. “We are excited to collaborate again with global oncology...
RHEA-AI
very positive
04/19/22 4:45 PM
Nasdaq : NVCR
Novocure Hosts Ceremonial Groundbreaking with New Hampshire Governor Chris Sununu
“Employers like Novocure help ensure New Hampshire remains the best state in which to live, work, and raise a family,” Gov. Sununu said.“ Thanks to our pro-jobs agenda, New Hampshire is the #1 state for business in New England, and I would like to congratulate the whole Novocure team on the groundbreaking for their latest expansion! “We thank Governor Sununu for his...
RHEA-AI
positive
04/08/22 7:00 AM
Nasdaq : NVCR
Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2022 Suggesting Broad Applicability of Tumor Treating Fields
Novocure today announced 19 presentations on Tumor Treating Fields will be delivered at the American Association for Cancer Research Annual Meeting 2022, to be held in New Orleans from April 8 to April 13, 2022. The research described in the presentations spans 10 tumor types and suggests the potential for broad usage of TTFields across multiple solid...
RHEA-AI
neutral